Treatment of Transformed Small Cell Lung Cancer Guided by Rebiopsy: A Case Report

doi:10.3877/cma.j.issn.2095-5782.2025.04.018

Abstract

Abstract:

On June 29, 2023, Tianjin People's Hospital admitted a female patient with advanced lung adenocarcinoma. The patient had undergone multiple lines of treatment，re-examination of the blood genetic test still indicated EGFR mutation, but targeted therapy was ineffective. The patient underwent another lung biopsy, which confirmed the pathology as small cell lung cancer. She received bronchial arterial infusion chemotherapy combined with molecular targeted therapy (Dacomitinib) and anti-angiogenesis therapy (Anlotinib), achieving partial response (PR) with a progression-free survival (PFS) of 4 months. During the treatment process, timely secondary biopsy indicated pathological transformation, and the combination of arterial infusion chemotherapy and targeted therapy successfully controlled the disease. This case may provide valuable insights for the treatment of transformed small cell lung cancer.

Key words: EGFR mutation, Gene mutation, Transformed SCLC, Rebiopsy, Arterial infusion chemotherapy

Shengnan Wu, Ning Mu, Mei Liu, Yue Xu, Huan Lv, Xinyi Wang, Chunhua Ma. Treatment of Transformed Small Cell Lung Cancer Guided by Rebiopsy: A Case Report[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2025, 13(04): 383-387.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2025.04.018

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2025/V13/I04/383

Figures/Tables 3

References 19

[1]	Pignataro D, Bertaglia V, Bironzo P, et al. Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules[J]. J Thorac Oncol, 2020, 15(10): e170-e172.
[2]	Cheng Y, He Y, Li W, et al. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study[J]. Target Oncol, 2021, 16(2): 165-176.
[3]	Westover D, Zugazagoitia J, Cho B C, et al. Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors[J]. Ann Oncol, 2018, 29(suppl_1): i10-i9.
[4]	Yu H A, Arcila M E, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J]. Clin Cancer Res, 2013, 19(8): 2240-2247.
[5]	Oser M G, Niederst M J, Sequist L V, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin[J]. Lancet Oncol, 2015, 16(4): e165-172.
[6]	Sequist L V, Waltman B A, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J]. Sci. Transl. Med, 2011, 3(75): 75ra26.
[7]	Roca E, Gurizzan C, Amoroso V, et al. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis[J]. Cancer Treat Rev, 2017, 59: 117-122.
[8]	Lee P H, Huang Y H, Lin H, et al. Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma[J]. Medicina, 2022, 58(7): 908.
[9]	Yin X, Li Y, Wang H, et al. Small cell lung cancer transformation: From pathogenesis to treatment[J]. Semin. Cancer Biol, 2022, 86(Pt 2): 595-606.
[10]	Gardner E E, Earlie E M, Li K, et al. Lineage-specific intolerance to oncogenic drivers restricts histological transformation[J]. Science, 2024, 383(6683): eadj1415.
[11]	Lee J K, Lee J, Kim S, et al. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas[J]. J Clin Oncol, 2017, 35(26): 3065-3074.
[12]	Marcoux N, Gettinger S N, O'kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes[J]. J Clin Oncol, 2019, 37(4): 278-285.
[13]	Zeng J, Ding X, Ding J, et al. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy[J]. Front Immunol, 2023, 14: 1275957.
[14]	郑华, 赵丹, 顾勐, et al. EGFR突变非小细胞肺癌治疗后发生小细胞肺癌转化的临床特征及预后分析[J]. National Medical Journal of China, 2024, 104(40): 3751-3756.
[15]	Wang W, Xu C, Chen H, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study[J]. Lung Cancer, 2021, 155: 20-27.
[16]	Lai L, Meng W, Wei J, et al. Transformation of NSCLC to SCLC after 1st-and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports[J]. Medicine (Baltimore), 2021, 100(10): e25046.
[17]	Ye X D, Yuan Z, Ye J D, et al. Assessment of the feeding arteries by three-dimensional computed tomography angiography prior to multi-arterial infusion chemotherapy for lung cancer[J]. Oncol Lett, 2013, 5(1): 363-367.
[18]	Hori S, Nakamura T, Kennoki N, et al. Transarterial management of advance lung cancer[J]. Jpn J Clin Oncol, 2021, 51(6): 851-856.
[19]	Zhang C Y, Sun H, Su J W, et al. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival[J]. Lung Cancer, 2023, 175: 68-78.

Please choose a citation manager

Content to export